AN2 Therapeutics, Inc.
ANTXHealthcare|Biotechnology|US
$4.00
+0.04 (+1.14%)
DCF Value
$0.59
Tangible Book / Share
$1.70
Cash / Share
$1.75
About
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Stock Price
+257.1%(1Y)
1M
-14.5%
3M
-32.5%
6M
-10.3%
YTD
+250.9%
1Y
+239.0%
3Y
-73.8%
5Y
-74.0%
Pipeline Summary
8 total trials4
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
Not Yet Recruiting: 1Completed: 5Terminated: 1Recruiting: 1
Active Trials (1)
Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
NCT07301320Mycobacterium Abscessus Infection
Phase 2Recruiting
Enrollment: 84 participants
Key Facts
Market Cap$150.9M
Employees21 (-5% YoY)
CEOEric E. Easom
IPO DateMar 25, 2022
Beta-0.94
52-Week Range$1 – $7.19
Avg Volume248,968
ExchangeNASDAQ
Websitean2therapeutics.com
Ownership
Float59.1%
Shares Outstanding37.7M
Recent Insider Trades
Eizen Joshua MSELL
Nov 5, 20262,826 shares @ $4.22
Marks Gilbert LynnAWARD
Oct 12, 20262,283 shares
Martin Patricia A.AWARD
Oct 12, 2026389 shares
Aziz KabeerAWARD
Oct 12, 20262,465 shares
Trenor Cameron C. IIIAWARD
Sep 15, 2026233,333 shares @ $5.36
Peers
Recent News
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Nov 4, 2026 · businesswire.com
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
Nov 2, 2026 · businesswire.com
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Oct 23, 2026 · businesswire.com
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
Oct 21, 2026 · businesswire.com
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Oct 20, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 03:55 AM